WFDC3 (WAP Four-Disulfide Core Domain 3)

This study presents a prediction model based on CD33, FANCD2, and TFPI, which could aid in individualized treatment decisions and provide a basis for further LUAD research.

Functionally, WFDC3 promoted PAAD cell metastasis by inducing epithelial-mesenchymal transition and contributed to immune evasion by suppressing T cell cytotoxicity. In conclusion, our study identifies WFDC3 as a pro-oncogenic factor in PAAD progression, highlighting its potential as both a prognostic biomarker and a therapeutic target for regulating metastasis and immune responses in this malignancy.

Conclusively, this study recognizes prospective biomarkers for breast cancer among Indian women and highlights the requisite of in-depth functional studies to elucidate their precise roles in breast cancer development. We particularly emphasize on SBSN and PFN1, as these proteins were observed to be progressively overexpressed and under expressed, respectively, in breast cancer samples compared to control samples, ranging from early-stage to metastatic cases.

Our results demonstrate that WFDC3 is possibly a biomarker for increasing oxaliplatin sensitivity in CRC by modulating ATM/ATR kinase signaling. Thus, a combination of oxaliplatin with an ATM or ATR inhibitor is a potential treatment option for improving CRC outcome.